Dialyzer Performance During Hemodialysis Without Systemic Anticoagulation Using a Heparin-Grafted Dialyzer Combined With a Citrate-Enriched Dialysate: Results of the Randomized Crossover Noninferiority EVOCIT Study.
The EVOCIT study was designed to evaluate dialyzer performance during hemodialysis with and without systemic anticoagulation.Randomized, crossover, non-inferiority trial. Noninferiority was defined as a difference of ≤10% for the primary outcome.Single hemodialysis center; 26 prevalent patients treated with 617 hemodialysis sessions.Hemodialysis using a heparin-grafted dialyzer combined with a 1.0 mmol/L citrate-enriched dialysate (“Evocit”) without systemic anticoagulation was compared to hemodialysis performed with a heparin-grafted dialyzer with systemic heparin (“Evohep”). Patients were randomly allocated to a first period of 4 weeks and crossed over to the alternative strategy for a second period of 4 weeks.The primary end point was the difference in Kt/Vurea between Evocit and Evohep. Secondary end points were urea reduction ratio (RR), middle molecule removal, treatment time, thrombin generation and reduction in dialyzer blood compartment volume.The estimated difference in Kt/Vurea between Evocit and Evohep was -0.03 (95%CI, -0.06 to -0.007) establishing non-inferiority with mean Kt/Vurea of 1.47±0.05 (SE) for Evocit and 1.50±0.05 for Evohep. Non-inferiority was also established for urea RR and beta-2 microglobulin RR. Premature discontinuation of dialysis was required for 4.2% of sessions among 6 patients during Evocit and no sessions during Evohep. Effective treatment time was 236±5 minutes for Evocit and 238±1 minutes for Evohep. Thrombin generation was increased, and there was greater reduction in dialyzer blood compartment volume after treatments with Evocit compared with Evohep.The effects of avoiding systemic anticoagulation on clinical outcomes were not evaluated.Evocit is non-inferior to Evohep with respect to solute clearance but results in a greater number of shortened treatments, more membrane clotting and greater thrombin generation.
View the full article @ American journal of kidney diseases : the official journal of the National Kidney Foundation
Authors: Karlien François, Dieter De Clerck, Annelies Tonnelier, Marie-Laure Cambier, Christelle Orlando, Kristin Jochmans, Wilfried Cools, Karl Martin Wissing